迈博药业-B2023中期报告

2 4 5 10 33 42 44 47 50 69 72 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands G79225300 8318A 183171712-1716 97927 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 50037 1 123 2181 www.mabpharm.cn 913 •CMAB008®S202100251234656CMAB008GMPCMAB008® CMAB008®1,000688136CMAB008®758%CMAB008®34GPOCMAB008® •CMAB007®S2023003075mgS20230031150mgIgECMAB007®H112 CMAB007®GPO4GPOCMAB007® •CMAB009CMAB009EGFRFOLFIRImCRCCMAB009CMAB009EGFRCMAB009mCRCEGFR CMAB009CMAB009CMAB009mCRCEGFRCMAB009CMAB009 CMAB009CMAB009CMAB009 CMAB807IIINDACMAB807X2022LP00032CMAB017EGFRCMAB017CMAB015CMAB819ICMAB015CMAB022 203863 5,000GMP40,000CDMO ®– CMAB008 CMAB008®TNFS20210025 (i)(ii)(iii)(iv)6(v)(vi) CMAB008®CMAB008®CHOTNFTNFCMAB008®TNFTNFCMAB008®CMAB008® CMAB008®CMAB008®1,000IBD CMAB008® CMAB008®758%CMAB008®34GPOCMAB008® ®CMAB007 CMAB007®IgEIgECMAB007®IgEIgEIgECMAB007®4824CMAB007®CMAB007®CMAB007® CMAB007®S2023003075mgS20230031150mgIgENDACMAB007®H112CXSL230037775mgCXSL2300378150mgCMAB007®NDACMAB007®CMAB007®CMAB007®GPO4GPOCMAB007® CMAB009 CMAB009EGFRFOLFIRImCRCCMAB009CMAB009EGFRCMAB009mCRCEGFR CMAB009NDACMAB009CMAB009mCRCEGFRCMAB009 2096 CMAB807RANKLBG2IgG2RANKLCMAB807RANKLRANKRANKLRANKCMAB807IIINDACMAB807 CMAB807CMAB807XCMAB807X CMAB819ICMAB819ICMAB819CMAB819 CMAB017EGFRCMAB017G1IgG1FcCMAB017CMAB017CMAB017CMAB017CMAB01724-72CMAB017 CMAB015secukinumabCMAB01517AIL-17ACMAB015ICMAB015 CMAB022®stelara®ustekinumabUstekinumab12IL-1223IL-23IL-12IL-23p40IL-12R1IL-12IL-232CMAB022 CMAB018mepolizumabCMAB018CMAB0185IL-5 CMAB023TSLPIgG2-lambdaTEZSPIRETezepelumabTSLPTSLPTSLPCMAB023 CMAB008CMAB007CMAB009NDACMAB807NDAGMP 30,000(i)3×1,500(ii)400(iii)100CMAB008CMAB007GMP 100,746(i)7,50018,000(ii)GMP40,000 CMAB00830PIC/s (i)(ii) GMPGMP PIC/s CMAB008CMAB007CMAB009CMAB807CMAB015CMAB022 28.852.6%44.0 11.143.9%6.2 12.570.0%3.7 2.96.1%2.7 78.023.7%59.5 47.81.4%47.2 3.144.9%4.5 9.5204.3%29.015.0100%0 39.7107.845.0 39.7 288100,74634.750,835105.349.018 412,4084,124,080,000 66.0%34.0%56.3%43.7% 100%66.0%56.3% (1)(2) 0.81.10.40.5 (1)(2) 1.10.80.50.4 1,144.51,005.1 383101282 (1)28 275180 XV(i)XV78(ii)352(iii) (1)4,124,080,000 (2)Asia Mabtech49.95%4.05%Asia MabtechAsia MabtechAsia Pacific Immunotech VentureAsia Pacific Immunotech VentureXV167,025,000Asia Mabtech2,059,975,000 (3) XVXV78352 336 (1)Asia Mabtech49.95%4.05%Asia Mabtech100%Asia MabtechAsia Pacific Immunotech VentureAsia Pacific Immunotech VentureXV167,025,000Asia Mabtech2,059,975,000(2)CDH PE18.00%CDH PECDH FundCDH FundCDH PECDH FundCDH VCDH VChina Diamond V80%ChinaDiamond VChina Diamond100%(3)FH InvestmentLink Best Capital LimitedLink Best Capital Limited 336 6283,512,50083,512,500202076,293,6501.85% 2410 13.1313.19 2096CMAB009CMAB009CMAB009CMAB009 Ernst & Young27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong 4468343434 2410 34 1. 190 Elgin Avenue, George Town, Grand Cayman KY1-9008,Cayman IslandsG79 Asia Mabtech Limited 2. 34 99,999,0001849,022,00043,672,000 2. 1.CMAB009CMAB0072.50 3. 1717171791281212 (a)12 3. (b)8 (c)1212 (i)7,472,000(ii)7,472,000 12 3. (d)12 4. 8 7,075,00021,106,000 5. 6. 7. 8. 9. 10. 11. 12. 13. 8,897,0007,319,000133,572,000132,570,000 14. a.100,746 15. 15. 16. 60 18. 100,74634,703,00035,089,00050,835105,320,000108,121,000 19. 20. (a) a.b.45,000,0003.7% 20. (b) 20. (b) 60 20. 21. FH InvestmentFortune-Healthy Investment Limited Guo Family (PTC) Limited CMAB816CMAB819IDNAEGFRHER22IBDIgEE GIgG75%IgGIgGBIgGIgGIgG12 34IgG1IgG150 kDa50 kDa25 kDakappa ()lambda()IgG11